Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Annovis Bio, Inc.NYSE: ANVS
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 46.5% from a year ago
Common stock stood at $2.85K at the end of Q1 FY2026, up 46.5% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +49.4% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +46.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 2.72K USD
- Year-over-year change
- +92.3%
- 4-year CAGR
- +35.4%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.72K | +92.3% |
| FY2024 | 2024-12-31 | 1.41K | +34.4% |
| FY2023 | 2023-12-31 | 1.05K | +28.9% |
| FY2022 | 2022-12-31 | 816 | +0.7% |
| FY2021 | 2021-12-31 | 810 | — |
Common Stock vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 common stock of $2.85K is the 5th highest of the 6 companies compared; the peer median is $6.07K.
- Its year-over-year change of +46.5% is the 3rd highest of 5, against a peer median of +36.4%.
- Common stock amounts to 0.0% of total assets for ANVS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $31K | +0.0% | +6.0% | 0.1% | |
| Mar 2026 | $18.42K | +22.8% | +22.1% | 0.1% | |
| Mar 2026 | $6.07K | +105.1% | +52.2% | 0.0% | |
| Dec 2025 | $3K | +50.0% | -41.5% | 0.0% | |
| Mar 2026 | $2.85K | +46.5% | +49.4% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ANVS) | $6.07K | +36.4% | +14.1% | 0.0% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.